SCHEMBL15610890

SCHEMBL15610890

OCc1cc([C@@H]2O[C@H](COCc3ccccc3)[C@@H](OCc3ccccc3)[C@H](OCc3ccccc3)[C@H]2OCc2ccccc2)ccc1Cl

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ PTPN1 P18031 5/20 0.43
▸ CDC25B P30305 5/20 0.43
▸ PTPN2 P17706 2/20 0.41
▸ PTPN6 P29350 2/20 0.41
▸ PTPN11 Q06124 2/20 0.41
▸ HTR1A P08908 1/20 0.41
▸ SLC5A2 P31639 4/20 0.41
▸ NT5E P21589 1/20 0.41
▸ TACR2 P21452 1/20 0.40
▸ SSTR1 P30872 1/20 0.39
▸ SSTR2 P30874 1/20 0.39
▸ SSTR4 P31391 1/20 0.39
▸ SSTR3 P32745 1/20 0.39
▸ SSTR5 P35346 1/20 0.39
▸ BCHE P06276 1/20 0.39
▸ SLC5A1 P13866 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9986263 1.00 PTPN1 (0.43) PTPN1CDC25BPTPN2PTPN6PTPN11
SCHEMBL20643059 1.00 PTPN1 (0.43) PTPN1CDC25BPTPN2PTPN6PTPN11
SCHEMBL2131297 1.00 PTPN1 (0.43) PTPN1CDC25BPTPN2PTPN6PTPN11
SCHEMBL9986268 1.00 PTPN1 (0.43) PTPN1CDC25BPTPN2PTPN6PTPN11
SCHEMBL2830061 0.89 HTR1A (0.41) PTPN1CDC25BPTPN2PTPN6PTPN11
SCHEMBL2130061 0.89 HTR1A (0.41) PTPN1CDC25BPTPN2PTPN6PTPN11
SCHEMBL15610303 0.89 HTR1A (0.41) PTPN1CDC25BPTPN2PTPN6PTPN11
SCHEMBL2464711 0.89 SLC5A2 (0.53) SLC5A2SLC5A1
SCHEMBL2133682 0.89 PTPN1 (0.43) PTPN1CDC25BPTPN2PTPN6PTPN11
SCHEMBL2130715 0.88 PTPN1 (0.39) PTPN1CDC25BPTPN2PTPN6PTPN11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2714032-B1 NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS GREEN CROSS CORP (KR) 2019-01-16 — — EP disclosed
EP-2714032-B1 NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS GREEN CROSS CORP (KR) 2019-01-16 — — EP disclosed
US-9371303-B2 Diphenylmethane derivatives as SGLT2 inhibitors GREEN CROSS CORPORATION (KR) 2016-06-21 — — US disclosed
US-20150152075-A1 NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS GREEN CROSS CORPORATION (KR) 2015-06-04 — — US disclosed
US-9034921-B2 Diphenylmethane derivatives as SGLT2 inhibitors GREEN CROSS CORPORATION (KR) 2015-05-19 — — US disclosed
US-20140088079-A1 NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS GREEN CROSS CORPORATION (KR) 2014-03-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140088079-A1 NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS SLC5A2, SLC5A1, SLC2A8 PTPN1 594/4885CDC25B 3494/4885PTPN2 384/4885
US-20150152075-A1 NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS SLC5A2, SLC5A1, SLC2A8 PTPN1 746/4885CDC25B 3943/4885PTPN2 505/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback